Young patient dies following Pfizer's experimental gene therapy
Shortpedia
Content Team
Image Credit: newsbytes
A young boy tragically lost his life due to sudden cardiac arrest after participating in a Pfizer medical trial. The child was suffering from Duchenne muscular dystrophy (DMD), and was part of Phase 2 DAYLIGHT — a multi-year clinical trial from the pharmaceutical company. Through this study, doctors were trying to assess the effectiveness of an experimental gene therapy named fordadistrogene movaparvovec. The boy's death has prompted scientists and parents to scramble in search of answers on how this happened.
